Paul A Friedman sold $10M of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 28,876 shares at an average of $353.19, traded Jul 16, 2025, filed Jul 18, 2025.
Score components
- +15RoleDirector
- +25Trade size$10.2M at market
- +5Share of holdings soldSold 14% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +10.7%, 3m +31.4%, 6m +50.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-035342, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 16, 2025 | MOption exercise Common Stock10b5-1 | +26,176 | $9.45 | $247k | 213,340 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -5,541 | $350.17 | $1.9M | 207,799 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -2,371 | $351.38 | $833k | 205,428 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -2,110 | $352.67 | $744k | 203,318 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -2,319 | $353.82 | $821k | 200,999 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -6,851 | $354.65 | $2.4M | 194,148 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -5,784 | $355.61 | $2.1M | 188,364 | Jul 18, 2025 |
| Jul 16, 2025 | SOpen-market sale Common Stock10b5-1 | -1,200 | $356.62 | $428k | 187,164 | Jul 18, 2025 |
| Jul 17, 2025 | MOption exercise Common Stock10b5-1 | +2,700 | $9.45 | $26k | 189,864 | Jul 18, 2025 |
| Jul 17, 2025 | SOpen-market sale Common Stock10b5-1 | -2,000 | $350.10 | $700k | 187,864 | Jul 18, 2025 |
| Jul 17, 2025 | SOpen-market sale Common Stock10b5-1 | -700 | $351.57 | $246k | 187,164 | Jul 18, 2025 |
| Jul 16, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -26,176 | $0.00 | $0 | 180,080 | Jul 18, 2025 |
| Jul 17, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -2,700 | $0.00 | $0 | 177,380 | Jul 18, 2025 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 30Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $342k 664 shares | -5% | |
| 35Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $1.4M 2,500 shares | -1% | |
| 21Weak | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $517k 1,042 shares | -9% | |
| 33Weak | MADRIGAL PHARMACEUTICALS, INC. | Richard S Levy director | $2.9M 5,682 shares | -21% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $435k 844 shares | -7% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $854k 1,982 shares | -14% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $181k 419 shares | -3% | |
| 41Moderate | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $155k 360 shares | -3% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub Pres., R&D, and CMO | $212k 491 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.